Scientists at Merck Research Laboratories (MRL) and their collaborators performed genetic and gene expression analysis of tissues from a model of metabolic syndrome (a group of conditions that increases the risk of cardiovascular disease and diabetes) and a human population known to be susceptible to obesity. The resulting data were analyzed using powerful computational methods that integrate data from several sources to identify networks of gene interactions altered in individuals susceptible to obesity... Merck's Press Release -
Blog Archive
-
▼
2008
(55)
-
▼
March
(13)
- Sanofi-aventis : NICE Recommends Acomplia to be in...
- deCODE Obesity Genetics study merck
- Arena Pharmaceuticals' Lorcaserin for Obesity
- VIVUS, Enrollment in EQUATE (OB-301) Trial completed
- Thiakis, Novel therapy for treatment of obesity en...
- Alizyme's cetilistat,Phase III development program...
- Merck, Innovative Research Method to Identify Chan...
- Marcadia Biotech and Merck, strategic collaboration
- Hollis-Eden Pharmaceuticals, Positive Preliminary ...
- Bar Harbor BioTechnology : New Line of StellARrays
- EnteroMedics, Expansion of EMPOWER Pivotal Study f...
- OREXIGEN Therapeutics, European Patent Office Allo...
- Athersys, Results for Phase 1 Safety Study of Its ...
-
▼
March
(13)
Friday, March 21, 2008
Merck, Innovative Research Method to Identify Changes in Gene Networks Linked to Obesity
Scientists at Merck Research Laboratories (MRL) and their collaborators performed genetic and gene expression analysis of tissues from a model of metabolic syndrome (a group of conditions that increases the risk of cardiovascular disease and diabetes) and a human population known to be susceptible to obesity. The resulting data were analyzed using powerful computational methods that integrate data from several sources to identify networks of gene interactions altered in individuals susceptible to obesity... Merck's Press Release -